Spruce Biosciences said it intends to implement cost savings initiatives, including termination of the CAHmelia-203 study and a workforce reduction of approximately 21%. The company currently has over $81M in cash and cash equivalents, which is anticipated to fund its current operating plan through the end of 2025, including through the CAHmelia-204 topline results and CAHptain-205 topline results from additional dosing cohorts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRB:
- SPRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Three new option listings on February 27th
- Spruce Biosciences price target raised to $9 from $8 at RBC Capital
- Guggenheim optimistic ahead of readouts, starts Spruce Biosciences at Buy
- Spruce Biosciences initiated with a Buy at Guggenheim
